Acquired immunodeficiency syndrome (AIDS)-related primary central nervous system lymphoma (AR-PCNSL) is an Epstein-Barr (EBV)-associated malignancy that occurs in severely immunocompromised human immunodeficiency virus (HIV)-infected patients.
Lack of EBV-specific CD4+ T-cells contributes to its pathogenesis 1 . Although AR-PCNSL incidence in the United States (US) decreased with availability of combination antiretroviral therapy (cART), 26 PCNSL cases per 100,000 person-years continue to occur in persons with AIDS, making up over 10% of US HIV-associated lymphoma cases. Prognosis remains poor, with greater than 75% 2-year mortality 2 . Neurologic comorbidities, difficulties distinguishing AR-PCNSL from other CNS pathology, undertreatment of AR-PCNSL and health care disparities may contribute to mortality 3 .
Central nervous system immune reconstitution inflammatory syndrome (CNS-IRIS) is
characterized by neurological deterioration despite immune recovery from an immunodeficient state. In AIDS patients with CNS opportunistic infections (OIs) such as
Cryptococcus, John Cunningham (JC) virus or cytomegalovirus (CMV) 4 , CNS-IRIS can complicate cART. CNS-IRIS is described as paradoxical when neurologic deterioration occurs despite cART and treatment of a known underlying CNS infection. Risk factors include low CD4+ nadir at time of cART initiation and rate of peripheral HIV viral load (VL) decay. Diagnosis is supported by neuroradiologic findings and in some cases, evidence of T-cell infiltration in pathological specimens 5 . CNS-IRIS is associated with high morbidity and mortality, largely attributed to exacerbated neuroinflammation associated with antigen specific T-cells 6 showed a dramatic decrease in the inflammatory CSF cells that was sustained 2 months after solumedrol (Table 1 Rapid response to steroids, decreased CSF inflammatory cells; lack of further lesions on repeat MRI, and maintained clinical improvement over 13 months after discontinuing steroids further support this diagnosis. Steroid responsiveness is unlikely due to treatment of refractory CNS lymphoma that by all other measures was responding to therapy.
Indeed, he obtained a complete response with the protocol-defined immunochemotherapy, and has no relapse during follow up. Interestingly, life-threatening CNS-IRIS in this case appears to be due to immune response in the CNS to the EBV+ tumor itself, although CNS-IRIS to occult pathogens cannot be fully excluded.
Severe CNS-IRIS represents a neurological emergency and steroids are indicated to mitigate additional CNS injury due to exaggerated immune response 11 . Duration of steroids depends on the specific antigenic stimuli, the antigenic burden and ability to treat the underlying CNS pathology. Benefits must be weighed against risk for other infectious complications in immunosuppressed patients. This case is the first report of treatment for EBV-associated AR-PCNSL complicated by paradoxical CNS-IRIS and demonstrates the importance of prompt recognition of this syndrome and potential reversibility.
Appendix

Treatment protocol
Patients Institutional Review Board, written informed consent was obtained.
Flow cytometry methods
CSF was immediately stabilized in RPMI with 10% fetal calf serum and processed within 4 hours of collection per consensus guidelines 13 . Cells were stained for 30 min at room temperature with an antibody panel assessing CD3, CD5, CD10, CD11c, CD13 9 , CD14, CD16, CD19, CD20, CD22, CD45, CD56, surface kappa and surface lambda 14 . Cells were fixed in 1.0% paraformaldehyde and stored at 4°C for up to 12 hours before acquisition. Specimens were acquired using an 8-color multiparametric approach on a 3- 
